Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AKTS compared with EIKN: revenue, margins and what each company keeps, and the suppliers and customers both name
AKTS
Aktis Oncology, Inc.
Change
Mkt cap
Revenue
Revenue
EIKN
Eikon Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
AKTS
Aktis Oncology, Inc.
vs
EIKN
Eikon Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
AKTS: latest quarter is a loss; flow not drawable. EIKN: latest quarter not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AKTS, solid
EIKN, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only AKTS
0
None
Shared
0
No disclosed counterparties: AKTS.
Only EIKN
4
MRK
MSD International Business GmbH
supplier
—
Impact Therapeutics (Shanghai)
unlisted
supplier
—
Seven and Eight Biotherapeutics
unlisted
supplier
—
Superb Wisdom
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
AKTS
Aktis Oncology, Inc.
Change
14.58
· pre 14.59
· delayed
Mkt cap
$806.8M
Revenue
$3M
Q2 FY26
EIKN
Eikon Therapeutics, Inc.
Change
5.68
· pre 5.60
· delayed
Pre-market
Nov 2 '26
delayed
Mkt cap
$287.5M
Revenue
—
vs
Compare
Pre-market
Nov 2 '26
delayed
AKTS
Aktis Oncology, Inc.
vs
EIKN
Eikon Therapeutics, Inc.
14.58
pre 14.59
delayed
Price
5.68
pre 5.60
delayed
$806.8M
Mkt cap
$287.5M
Q2 FY26
$3M
Revenue
—
Change
Change
AKTS
14.58
vs
EIKN
5.68
Pre-market
Nov 2 '26
delayed